Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, outlines results from GEM-CESAR (NCT02415413), a Phase II trial which investigated abrogating the risk of smoldering multiple myeloma progression through an intensive treatment regimen (carfilzomib, lenalidomide and dexamethasone as induction followed by high-dose chemotherapy and autologous transplantation. Overall, sustained measurable residual disease (MRD) negativity translated to longer periods before transformation to multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Honoraria, Research Funding; Adaptive: Honoraria; GSK: Honoraria, Research Funding; EngMab: Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Roche Glycart AG: Honoraria, Research Funding; Amgen: Honoraria; Gilead: Honoraria; Oncopeptides: Honoraria.